Literature DB >> 1459728

Neutralizing activity of human antibodies against the structural protein of human T-cell lymphotropic virus type I.

Y Inoue1, N Kuroda, H Shiraki, H Sato, Y Maeda.   

Abstract

We have identified and mapped the regions responsible for neutralization in the human T-cell leukemia virus type I (HTLV-I) structural proteins by using region-specific human antibodies derived from seropositive blood donors. We have obtained 18 kinds of region-specific antibody (2 in the p19 gag, 10 in the gp46 env and 6 in the gp21 env proteins) from seropositive human plasma by means of an affinity column coupled with the synthetic peptides corresponding to the antigenic regions of the HTLV-I structural proteins. These antibodies were highly specific in ELISA using synthetic peptides as an antigen. Subsequently, we examined the neutralizing activity expressed by the inhibition of virion-induced syncytium formation by region specific antibodies. Twelve of 16 antibodies derived from the env protein were able to inhibit syncytium formation induced by co-cultivation of 8C cells with HTLV-I antigen-positive T cells. The antibodies derived from the p19 gag protein and the seronegative plasma used as the control showed no significant activity. The sequences recognized by the 10 neutralizing antibodies were sites corresponding to amino acids 20 to 49, 89 to 115, 136 to 160, 175 to 199, 213 to 236, 235 to 254, 277 to 292, 332 to 352, 350 to 386, 382 to 403, 426 to 448 and 458 to 488 from the amino terminal of the env protein. These observations suggest that the neutralizing epitopes were widely distributed in the env proteins of HTLV-I.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1459728     DOI: 10.1002/ijc.2910520608

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Diversity of intrathecal antibody synthesis against HTLV-I and its relation to HTLV-I associated myelopathy.

Authors:  B Kitze; K Usuku; S Izumo; M Nakamura; H Shiraki; S Ijichi; S Yashiki; T Fujiyoshi; S Sonoda; M Osame
Journal:  J Neurol       Date:  1996-05       Impact factor: 4.849

2.  Trypsin-sensitive and -resistant components in human T-cell membranes required for syncytium formation by human T-cell lymphotropic virus type 1-bearing cells.

Authors:  Y Sagara; C Ishida; Y Inoue; H Shiraki; Y Maeda
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

3.  HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165.

Authors:  Sophie Lambert; Manuella Bouttier; Roger Vassy; Michel Seigneuret; Cari Petrow-Sadowski; Sébastien Janvier; Nikolaus Heveker; Francis W Ruscetti; Gérard Perret; Kathryn S Jones; Claudine Pique
Journal:  Blood       Date:  2009-03-06       Impact factor: 22.113

4.  Identification and mapping of functional domains on human T-cell lymphotropic virus type 1 envelope proteins by using synthetic peptides.

Authors:  Y Sagara; Y Inoue; H Shiraki; A Jinno; H Hoshino; Y Maeda
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

Review 5.  Human T Lymphotropic Virus Type I (HTLV-I) Oncogenesis: Molecular Aspects of Virus and Host Interactions in Pathogenesis of Adult T cell Leukemia/Lymphoma (ATL).

Authors:  Sanaz Ahmadi Ghezeldasht; Abbas Shirdel; Mohammad Ali Assarehzadegan; Tahereh Hassannia; Hosian Rahimi; Rahele Miri; S A Rahim Rezaee
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

6.  Provirus load in patients with human T-cell leukemia virus type 1 uveitis correlates with precedent Graves' disease and disease activities.

Authors:  A Ono; E Ikeda; M Mochizuki; M Matsuoka; K Yamaguchi; T Sawada; S Yamane; S Tokudome; T Watanabe
Journal:  Jpn J Cancer Res       Date:  1998-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.